Navigation Links
New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy
Date:7/18/2011

MONTGOMERY, Ala. and INDIANAPOLIS, July 18, 2011 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) today released new study results that investigated the potential interaction of cholesterol drug LIVALO (pitavastatin) 4 mg in healthy volunteers taking the protease inhibitor (PI) combination lopinavir/ritonavir, a fixed dose combination drug for the treatment of HIV infection.(1)  Protease inhibitors are commonly used antiretroviral HIV medications.(2)  The study, presented at the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy, found that when co-administered, the individual drug blood levels for LIVALO or each of the PIs was minimally affected.  Based on these data from this FDA-mandated phase IV study, the United States Food and Drug Administration recently approved a labeling change to delete the lopinavir/ritonavir limitation of use from the U.S. LIVALO labeling.

(Logo:  http://photos.prnewswire.com/prnh/20100621/NY23523LOGO)

"HIV is a chronic illness today, as opposed to 30 years ago, and patients with HIV are faced with additional challenges concerning dyslipidemia, accentuated by both the disease process as well as antiretroviral therapies. Additionally, these patients are frequently on multiple medications and the management of dyslipidemia can be even more of a challenge. We are pleased with the results of this study and the absence of a significant drug interaction when LIVALO is co-administered with this combination of protease inhibitors," said Craig Sponseller, MD, Vice President of Medical Affairs, Kowa Pharmaceuticals America, Inc.  

The study was designed to assess the pharmacokinetic (PK) interaction, or effect on overall exposure in the body, of th
'/>"/>

SOURCE Kowa Pharmaceuticals America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
2. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
3. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
4. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
5. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
6. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
7. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
8. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
9. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... The ophthalmic therapeutics company Xcovery Vision announced today that ... Ken Mandell, President and COO, will be speaking at ... Annual Meeting in Fort Lauderdale Florida, May 1-5, 2011. ... recounts his repeated success as founder of multiple ...
... Accuracy in radiation therapy demands careful targeting and ... Farber Center for Radiation Oncology , the first and ... is among the first treatment centers to adopt Elekta,s ... patient positioning system that enables clinicians to fine-tune ...
Cached Medicine Technology:Xcovery Vision Founders to Speak at ARVO 2011 2Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer 2
(Date:4/24/2014)... terminology, and the relevance of palliation in advanced ... randomized controlled trials (RCTs). This is the result ... Quality and Efficiency in Health Care (IQWiG), which ... Together with external experts, IQWiG analysed studies on ... malignant melanoma, and pancreatic cancer. For this purpose, ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
(Date:4/23/2014)... J. O,Shea, M.D., scientific director at the National Institute ... been named the 2014 recipient of the Ross Prize ... open-access journal Molecular Medicine . The award will ... Academy of Sciences in Manhattan, followed by scientific presentations ... part of the National Institutes of Health. , The ...
(Date:4/23/2014)... researchers have identified an important enzyme pathway that helps ... few chromosomes, a condition that has been directly linked ... professor of biochemistry, found that near the end of ... that ensures any breaks in DNA are fully repaired ... to daughter cells. This process helps safeguard against some ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of herbal products and medicines has the potential to reach ... the creation of exclusive export promotion zones (EPZ) across ... can be accelerated with the setting up of EPZs in ... rate of over 25 percent in countries like the US, ...
... as marijuana or ganja, can help in the treatment ... body tissues are attacked by its own immune system. ... University of Bonn, used tetrahydrocannabinol (THC), the active ingredient ... that it reduced skin allergies. ,However, the ...
... Today at the 61st Annual Meeting of the ... Cordis Corporation, announced the worldwide launch of the ... use in angioplasty procedures for patients with carotid ... a unique high-pressure expansion and low profile .014 ...
... better way to say "I love you" than showing your Dad ... come . This Father's Day, the American Diabetes Association (ADA) wants ... out by their doctor. ,More than 10 percent of all ... 2 diabetes, the most common form of the disease, can come ...
... number of suicide attempts among asylum seekers in Denmark has ... of despair," according to a study published Thursday . ... camps -- or 0.6 percent of the total -- tried ... by the Danish Association to Help Refugees said. ...
... for a new study has found that regular practice ... as well as the cognitive decline associated with ... practice, is centred on attentional and postural self-regulation and ... normal age-related decline of cerebral gray matter volume and ...
Cached Medicine News:Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty 2Health News:Drag Dad to the Doctor This Father's Day 2
... Aestiva/5 Pendant anesthesia machine offers proven ... range with the SmartVent ventilator. However, ... superior ventilation. Enhancements in flexibility, ergonomics ... in anesthesia delivery., ,The Aestiva/5 ...
With its integrated design and superior build quality each Prima SP is custom built to meet your requirements....
... Tegagel hydrogel wound filler and ... are amorphous hydrogel dressings specially formulated ... that has been shown to enhance ... formula meets clinical needs for management ...
Features various cylinder sizes and a simple two-handed pumping mechanism....
Medicine Products: